Carboxy Or Salt Thereof Only Attached Indirectly To The Benzene Ring Patents (Class 514/570)
-
Publication number: 20130237559Abstract: The present invention provides sustained-release oral pharmaceutical compositions and methods of use. The sustained-release oral pharmaceutical compositions include an amine-containing compound (e.g., an opioid) (including salts thereof) and a pharmaceutically acceptable salt of a non-NSAID cyclic organic acid compound.Type: ApplicationFiled: June 29, 2011Publication date: September 12, 2013Inventors: Ronnie Ortiz, James S. Jensen, Kristopher R. Lundell, Victoria Ann O'Neill, Sean Mahoney
-
Publication number: 20130231390Abstract: Pharmaceutical composition of ibuprofen for injection that comprises an aqueous solution of ibuprofen and trometamol. These compositions display a minimal loss of active principle and acceptable increase of impurities after autoclaving, properties that have been demonstrated in various types of containers, such as containers made of plastics such as polypropylene, PVC and polyethylene, as well as in glass containers. These compositions, after undergoing autoclaving, still comply with all the relevant technical specifications of the European Pharmacopoeia and of the USP.Type: ApplicationFiled: May 18, 2011Publication date: September 5, 2013Applicant: SPAIN PHARMA, S.A.Inventors: Ignacio Ortúzar Andéchaga, Mario Ortúzar Gutiérrez
-
Patent number: 8524748Abstract: Described herein are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.Type: GrantFiled: October 7, 2009Date of Patent: September 3, 2013Assignee: Panmira Pharmaceuticals, LLCInventors: John Howard Hutchinson, Thomas Jon Seiders, Jeannie M. Arruda, Jeffrey Roger Roppe
-
Publication number: 20130225683Abstract: New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I, Formula I, IA, IB and IC, and their pharmaceutical acceptable salts are described for prevention or treatment of diabetes or a diabetes-related disorder in a subject in need thereof. Diabetes and diabetes-related disorder include Type I diabetes, Type II diabetes, maturity-onset diabetes of the young, latent autoimmune diabetes of adults (LADA), gestational diabetes, diabetic nephropathy, proteinuria, ketonuria, obesity, hyperglycemia, glucose intolerance, insulin resistance, hyperinsulinemia, hypercholesterolemia, hypertension, hyperlipoproteinemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, metabolic syndrome, syndrome X, diabetic neuropathy, diabetic retinopathy, hypoglycemia, cardiovascular disease, atherosclerosis, diabetic kidney disease, ketoacidosis, thrombotic disorders, sexual dysfunction, dermatopathy, edema, metabolic syndrome and renal disorders.Type: ApplicationFiled: October 26, 2011Publication date: August 29, 2013Applicant: PROMETIC BIOSCIENCES INC.Inventors: Lyne Gagnon, Brigette Grouix, Pierre Laurin
-
Publication number: 20130224123Abstract: The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.Type: ApplicationFiled: December 4, 2012Publication date: August 29, 2013Applicant: Alkermes Pharma Ireland LimitedInventor: Alkermes Pharma Ireland Limited
-
Publication number: 20130225685Abstract: An intravenous composition for providing relief for pain and/or inflammation, the composition having ibuprofen and paracetamol in combination for delivering to a human at each dose: a) approximately 125 mg to approximately 175 mg ibuprofen in combination with approximately 475 mg to approximately 525 mg paracetamol; or b) approximately 275 mg to approximately 325 mg ibuprofen in combination with approximately 975 mg to approximately 1,025 mg paracetamol.Type: ApplicationFiled: October 26, 2011Publication date: August 29, 2013Applicant: AFT Pharmaceuticals LimitedInventor: Hartley Campbell Atkinson
-
Publication number: 20130225538Abstract: A bimodal bioabsorbable polymer composition. The composition includes a first amount of a bioabsorbable polymer polymerized so as to have a first molecular weight distribution; a second amount of said bioabsorbable polymer polymerized so as to have a second molecular weight distribution having a weight average molecular weight between about 10,000 to about 50,000 Daltons, the weight average molecular weight ratio of said first molecular weight distribution to said second molecular weight distribution is at least about two to one; wherein a substantially homogeneous blend of said first and second amounts of said bioabsorbable polymer is formed in a ratio of between about 50/50 to about 95/5 weight/weight percent. Also disclosed are a medical device, a method of making a medical device and a method of melt blowing a semi-crystalline polymer blend.Type: ApplicationFiled: March 15, 2013Publication date: August 29, 2013Applicant: ETHICON, INC.Inventor: ETHICON, INC.
-
Publication number: 20130224291Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.Type: ApplicationFiled: March 20, 2013Publication date: August 29, 2013Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: Wellesley Pharmaceuticals, LLC
-
Patent number: 8518997Abstract: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.Type: GrantFiled: December 21, 2011Date of Patent: August 27, 2013Assignee: Janssen Pharmaceutica N.V.Inventors: Gee-Hong Kuo, Rui Zhang, Aihua Wang, Alan R. DeAngelis
-
Publication number: 20130217772Abstract: The present invention is a novel pharmaceutical formulation that compromises a four mg per ml (4 mg/mL) Ibuprofen in an aqueous solution of Arginine and Ibuprofen, wherein the molar ratio of Arginine to ibuprofen is more than or equal to 1.000625:1, Tris buffered, isotonic, and adjusted to pH between 7.2-8.5 by addition of 1.0 N HCL, none of the excipients used contains material of animal or human origin. There were no novel excipients used. The present invention also provides a method of treating through anti-inflammatory, analgesic, and antipyretic activity: fever, pain, dysmenorrhea and inflammatory diseases such as rheumatoid arthritis and muscles. It is also used for pericarditis and patent ductus arteriosus (Patent ductus arteriosus (PDA)), relieve moderate to severe pain, dental pain and pain after an operation, also relieve mild to moderate pain including migraine headache, as well as for short term treatment of pyrexia in children over one year of age.Type: ApplicationFiled: February 19, 2013Publication date: August 22, 2013Applicant: PHARMACEUTICAL SOLUTIONS INDUSTRY LTD.Inventor: Pharmaceutical Solutions Industry Ltd.
-
Publication number: 20130217774Abstract: Preparing a dexibuprofen pharmaceutical formulation in the form of granules that can be directly compressed into tablets. The process consists of two steps: (i) preparation of base granules, and (ii) blending base granules with a compression aid. The process of preparing base granules involves use of liquid bed granulator with top spray method, or slugging by roll compaction. The granules prepared by using both the methods showed improved compressibility and flowability compared to granules prepared by conventional granulation process using rapid mixer granulator. The ready-to-compress granules prepared by the process show no signs of sticking when compressed on a high-speed commercial scale tablet compression machine.Type: ApplicationFiled: October 24, 2011Publication date: August 22, 2013Inventors: Vivekanandan Sundaramoorthy, Anandsenthilvel Palanisamy, Sampathkumar Devarajan, Jeffrey Stuart Bergman
-
Publication number: 20130217773Abstract: This invention is designed for the convenient and reliable delivery of predetermined doses of topical therapeutic medications applied to the skin. The importance of this method of application is that it allows reducing the amount of a therapeutic agent used in one session or reducing amount of sessions per day by eliminating the application of medications to a treating surface by hand. The emphasis is on making therapeutic agents available for self-administration, especially for partially disabled people with conditions such as arthritis and/or visual impairments who would not be able to use these medications without assistance.Type: ApplicationFiled: February 22, 2012Publication date: August 22, 2013Inventor: Mikhail Levitin
-
Publication number: 20130217645Abstract: New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I, Formula I.1, Formula I.2, Formula IA, Formula IB, Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of a combination of two of these compounds is described and the use of the combination of one of these compounds with an anticancer agent such as decarbazine, doxorubicin, daunorubicin, cyclophosphamide, busulfex, busulfan, vinblastine, vincristine, bleomycin, etoposide, topotecan, irinotecan, taxotere, taxol, 5-fluorouracil, methotrexate, gemcitabine, cisplatin, carboplatin and chlorambucil.Type: ApplicationFiled: October 26, 2011Publication date: August 22, 2013Applicant: PROMETIC BIOSCIENCES INC.Inventors: Lyne Gagnon, Brigitte Grouix, Lilianne Geerts, Pierre Laurin, Christopher Penney, Boulos Zacharie
-
Publication number: 20130216620Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.Type: ApplicationFiled: March 20, 2013Publication date: August 22, 2013Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: Wellesley Pharmaceuticals, LLC
-
Publication number: 20130209433Abstract: Methods for reducing peripheral blood glucose levels, food intake, glucose production, gluconeogenesis, triglyceride levels, and low density lipoprotein (VLDL) levels in mammals are provided. Also provided are methods of increasing glucose production and food intake in mammals. Further provided are methods of treating a disorder selected from the group consisting of obesity, type 2 diabetes, type 1 diabetes, hyperglycemia, insulin resistance, glucose intolerance, leptin resistance, metabolic syndrome, heart failure, ischemia, coronary heart disease, familial lipoprotein lipase deficiency, hypopituitarism, hyperlipidemia, hypertriglyceridemia, hyper-VLDLemia, atherosclerosis, hypercholesterolemia, hypertension, and any combination of the foregoing. The methods involve manipulations of amino acid presence or metabolism in the hypothalamus of the mammal.Type: ApplicationFiled: December 12, 2012Publication date: August 15, 2013Applicant: Albert Einstein College of Medicine of Yeshiva UniversityInventor: Albert Einstein College of Medicine of Yeshiva University
-
Publication number: 20130203602Abstract: The present invention relates to biologically active compounds, particularly liquid compounds, which are immobilized on a solid carrier material, particularly on mesoporous silica. The compounds are non-covalently supported on the solid carrier material thereby forming stable, easily handled solids which have the further advantage that the adsorbed biologically active compounds have improved thermal stability compared with the non-adsorbed compounds, and that they are released rapidly and completely from the carrier material when placed in an aqueous environment.Type: ApplicationFiled: March 11, 2011Publication date: August 8, 2013Applicants: Danmarks Tekniske Universitet, The Board of Trustees Of The Univ. Of Alabama For And On Behalf Of The Univ. Of Alabama, The Queens University of BelfastInventors: Anders Riisager, Rasmus Fehrmann, Hector Rodriguez, Katharina Bica, Robin D. Rogers, Daniel T. Daly, Gabriela Gurau
-
Publication number: 20130203723Abstract: The present invention relates to solubility improving preparation for enhancing the oral absorption of a poorly soluble drug, which is comprising (A) and (B); (A) a granulated substance which comprises (i) a poorly soluble drug having an acidic group in the molecule, (ii) an alkaline agent, (iii) a surfactant, and this granulated substance dose not substantially contain a disintegrator, (B) a disintegrator existing only in the external of the granulated substance.Type: ApplicationFiled: September 29, 2011Publication date: August 8, 2013Inventors: Satoshi Sakuma, Hiroshi Ueda, Akira Mashimo, Hiroshi Murazato
-
Patent number: 8501228Abstract: Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.Type: GrantFiled: September 14, 2012Date of Patent: August 6, 2013Assignee: Horizon Pharma USA, Inc.Inventors: Jerry Xu, George F. Tidmarsh
-
Publication number: 20130197089Abstract: Ibuprofen can be used in the prevention and treatment of actinic keratosis.Type: ApplicationFiled: January 30, 2013Publication date: August 1, 2013Applicant: DOLORGIET GMBH & CO. KGInventor: Juergen Warnecke
-
Publication number: 20130196012Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: WELLESLEY PHARMACEUTICALS, LLC
-
Publication number: 20130196956Abstract: A method for reducing the frequency of urination is disclosed. The method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents and one or more ?-blockers. In one embodiment, the one or more analgesic agents are formulated for extended-release.Type: ApplicationFiled: March 14, 2013Publication date: August 1, 2013Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: Wellesley Pharmaceuticals, LLC
-
Publication number: 20130197085Abstract: [Problems to be Solved] It is an object of the present invention to provide an agent and a method for maintaining and promoting the stability of a membrane protein, and in particular, a transporter (for example, an ABC transporter) on a cell membrane.Type: ApplicationFiled: November 18, 2011Publication date: August 1, 2013Inventors: Yuichi SUGIYAMA, Hisamitsu HAYASHI, Takuya KATO
-
Patent number: 8497304Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).Type: GrantFiled: January 19, 2012Date of Patent: July 30, 2013Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Shirou Sawa, Shuhei Fujita
-
Patent number: 8497303Abstract: A method to enhance solubility of an active compound comprises combining an active compound, having an aqueous solubility that is less than or equal to about 10 mg/mL, and an amount of methoxypolyethylene glycol that is sufficient to increase the aqueous solubility of the active compound. Enhancement of aqueous solubility for this combination may be significantly greater than that of an active compound in combination with an equivalent amount of polyethylene glycol. Particularly enhanced solubility is shown where a small amount of water is also included. The invention may be used in a wide variety of applications, such as for pharmaceutical, agricultural, antimicrobial, and personal care products.Type: GrantFiled: January 5, 2009Date of Patent: July 30, 2013Assignee: Dow Global Technologies LLCInventors: David B. Wurn, David A. Wilson, Bruce A. Barner, Cynthia L. Rand, Matthew D. Miller, Michael J. Johnson
-
Patent number: 8497257Abstract: The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent.Type: GrantFiled: October 24, 2008Date of Patent: July 30, 2013Assignee: Amderma Pharmaceuticals, LLCInventor: Pedro Cuevas Sanchez
-
Publication number: 20130190340Abstract: Certain aspects of the invention relate to compounds, compositions and methods that are useful for treating or preventing a disease in a subject by enhancing the degradation of a protein. In other aspects, said compounds can be useful research tools for investigating protein degradation. In other aspects, said compounds are useful research tools for investigating protein function. In certain embodiments, the degraded protein is implicated in a disease or disorder whose pathology is related at least in part to the excessive expression of the protein or the expression of a mutant form of the protein.Type: ApplicationFiled: June 30, 2011Publication date: July 25, 2013Applicant: Brandeis UniversityInventors: Lizbeth K. Hedstrom, Marcus Long, Deviprasad R. Gollapalli
-
Publication number: 20130190333Abstract: A combination comprising as components (a) the compound 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and (b) one or more non-steroidal anti-inflammatory drugs (NSAIDs); a pharmaceutical salt comprising said components; a compound derived from said components; a pharmaceutical formulation and a dosage form comprising said combination, salt, or compound; as well as a method of treating pain, e.g. chronic or acute pain, in a mammal characterized in that components (a) and (b) are administered simultaneously or sequentially to a mammal, wherein component (a) may be administered before or after component (b) and wherein components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.Type: ApplicationFiled: January 30, 2013Publication date: July 25, 2013Applicant: GRUENENTHAL GmbHInventor: GRUENENTHAL GmbH
-
Publication number: 20130190403Abstract: A method for treating human patients who require hospitalization for a trauma injury wherein the patients are intravenously administered a first dose of a therapeutically effective dose of ibuprofen intravenously as soon as possible after hospitalization is disclosed. The patients are further treated with intravenous ibuprofen at suitable dosing intervals to the human patient until (a) the patient no longer requires intravenous dosing of ibuprofen.Type: ApplicationFiled: January 23, 2012Publication date: July 25, 2013Applicant: Cumberland Pharmaceuticals Inc.Inventors: Leo Pavliv, Amy Dix Rock
-
Patent number: 8492367Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.Type: GrantFiled: June 6, 2011Date of Patent: July 23, 2013Assignee: AmDerma Pharmaceuticals, LLCInventors: Pedro Cuevas Sánchez, Guillermo Gimenez Gallego, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
-
Patent number: 8492438Abstract: Disclosed are a composition and a method for treating skin disorders, including rosacea, pityriasis rosea, erythema, rhinophyma, and rosacea-associated disorders including pimples, papules, pustules, and telangiectasia.Type: GrantFiled: February 4, 2011Date of Patent: July 23, 2013Assignee: Asan Laboratories Company (Cayman), LimitedInventors: Yih-Lin Chung, Nam-Mew Pui, Wei-Wei Chang
-
Publication number: 20130177609Abstract: An ophthalmic composition comprises an ophthalmic drug that has a low solubility in water and a surfactant, wherein the ophthalmic drug is present at a concentration from about 3 to about 7000 times the solubility of the drug in water. A volume of about 1-15 microliter is administered topically to an eye of a subject to treat or control a condition for which the drug is effective.Type: ApplicationFiled: February 27, 2013Publication date: July 11, 2013Inventor: Bausch & Lomb Incorporated
-
Publication number: 20130178448Abstract: This invention relates to the treatment of respiratory disorders, and in particular respiratory disorders and oedema caused by pathogenic infections. In particular, the invention relates to orally administrable pharmaceutical compositions for treating respiratory disorders, and to methods of such treatment. The invention is particularly concerned with the treatment of respiratory disorders that are caused by viral infections, such as with influenza viral strains. The invention also extends to analgesic compositions and methods for treating inflammatory pain manifesting in a variety of diseases, and not only respiratory diseases.Type: ApplicationFiled: February 4, 2011Publication date: July 11, 2013Inventors: Wilson Caparros-Wanderley, John Brew, Gregory Stoloff, Robin Mark Bannister
-
Publication number: 20130172419Abstract: A polymer composite composition wherein at least one of the constituents is a silicone ionomer and the other constituent is polymer.Type: ApplicationFiled: December 20, 2012Publication date: July 4, 2013Applicant: Momentive Performance Materials Inc.Inventor: Momentive Performance Materials Inc.
-
Publication number: 20130165505Abstract: Administration of certain 1-phenylalkanecarboxylic acid derivatives is useful for improving Cognitive Function; treating Cognitive Impairment, in particular Mild Cognitive Impairment; and preventing and/or reducing the risk of developing Alzheimer's Disease in a cognitively normal subject.Type: ApplicationFiled: December 21, 2012Publication date: June 27, 2013Applicant: Chiesi Farmaceutici S.p.A.Inventor: Chiesi Farmaceutici S.p.A.
-
Publication number: 20130165518Abstract: Provided herein are compositions and methods of making compositions of ibuprofen in combination with a narcotic analgesic. Specifically provided is a pharmaceutical tablet composition comprising ibuprofen; a narcotic analgesic; colloidal silicon dioxide; a filler selected from the group consisting of microcrystalline cellulose and powdered cellulose; a disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, and sodium starch glycolate; a binder consisting of an akylhydroxy methylcellulose; a starch; and a lubricant.Type: ApplicationFiled: December 7, 2012Publication date: June 27, 2013Applicant: ABBVIE DEUTSCHLAND GMBH & CO. KGInventor: AbbVie Deutschland GmbH & Co. KG
-
Publication number: 20130165486Abstract: Tetrasubstituted benzenes that act as modulators of gamma secretase and their use in the treatment of one or more symptoms of treating neurodegenerative disorders, e.g., Alzheimer's disease, are described.Type: ApplicationFiled: February 1, 2013Publication date: June 27, 2013Applicant: ENVIVO PHARMACEUTICALS, INC.Inventor: ENVIVO PHARMACEUTICALS, INC.
-
Patent number: 8470886Abstract: The present application relates to a topical formulation comprising ibuprofen, a hydroalcoholic based solvent system, a C1-4alcohol ester of citric acid, and a surfactant. The formulation shows physical stability over more than one month at ambient temperature and is colorless, essentially odorless, and has a pH value of about 6.5. The formulation of the application shows two to four times improved ibuprofen flux compared to a standard composition.Type: GrantFiled: November 26, 2010Date of Patent: June 25, 2013Assignee: NUVO Research Inc.Inventors: Dominic King-Smith, Bradley S. Galer, John M. Newsam, Nadir Buyuktimkin, Servet Buyuktimkin, Edward T. Kisak, Jagat Singh
-
Patent number: 8470831Abstract: Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R?, R?, W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them.Type: GrantFiled: September 23, 2009Date of Patent: June 25, 2013Assignee: Cogenia SRLInventors: Daniele Fancelli, Mario Varasi, Simon Plyte, Marco Ballarini, Anna Cappa, Giacomo Carenzi, Saverio Minucci, Gilles Pain, Manuela Villa
-
Publication number: 20130150381Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of dis orders related to aberrant levels of uric acid.Type: ApplicationFiled: June 15, 2011Publication date: June 13, 2013Applicant: ARDEA BIOSCIENCE, INC.Inventors: Samedy Ouk, Jean-Michel Vernier, Esmir Gunic
-
Publication number: 20130149353Abstract: A solid dosage form designed to facilitate rapid and reliable oral, esophageal and GI transit has a surface area of the contact patch, i.e., the area of contact between the dosage form and the bodily surface reduced. The dosage form can be an asymmetric oral dosage unit containing a bioactive, the dosage unit being asymmetric with respect to a rotational axis perpendicular to a longitudinal axis of the dosage form, the rotational axis being located substantially at a mid point along the longitudinal axis. The dosage unit may have an outer surface ridged or dimpled or have at least one annular ring so as to reduce the contact patch of the dosage unit with a flat surface compared to non-ridged dosage unit of the same size and shape. The oral dosage unit can also have a spherical shape with or without ridges and/or dimples. Dies for forming these oral dosage units have, in a closed state, a cavity having a shape corresponding to the oral dosage unit.Type: ApplicationFiled: February 5, 2013Publication date: June 13, 2013Inventors: Richard C. FUISZ, Joseph M. FUISZ
-
Publication number: 20130149380Abstract: The present invention is related to solid pharmaceutical preparations containing diatomaceous earth (diatomite) or a natural mineral mixture containing diatomaceous earth as filler besides the active ingredient and optional other auxiliary agents. A further object of the invention is a method for manufacturing such pharmaceutical preparations.Type: ApplicationFiled: May 27, 2011Publication date: June 13, 2013Applicants: ONP HOLDINGS SE, EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAGInventors: Endre Mikulásik, Ottó Albrecht
-
Publication number: 20130149282Abstract: The disclosure relates to edible and biodegradable eating utensils and edible and biodegradable containers. In one aspect a method of making and preserving an edible and biodegradable utensil or container is disclosed.Type: ApplicationFiled: December 10, 2012Publication date: June 13, 2013Inventor: David Christopher Marshall
-
Publication number: 20130150321Abstract: A pharmaceutical dosage form is provided comprising a non-steroidal anti-inflammatory agent and acetaminophen, and methods for their use. In one embodiment, the dosage form is comprised of ibuprofen and acetaminophen as the sole pharmaceutically effective agents, wherein the ibuprofen and acetaminophen are in a weight ratio of about 12 parts:about 88 parts.Type: ApplicationFiled: February 6, 2013Publication date: June 13, 2013Applicant: MCNEIL-PPC, INC.Inventor: McNeil-PPC, Inc.
-
Publication number: 20130149381Abstract: A method for preparing polymeric nanoparticles having entrapped active ingredients or drugs, the method includes the step of preparing a reaction by mixturing water, a surfactant, and a water-soluble radical initiator; polymerizing a polymerizable monomer in the reaction to obtain a dispersion of polymeric nanoparticles having a controlled size with average diameters smaller than 50 nm; dissolving one or more active ingredients in a suitable solvent; adding the solution of active ingredients to the dispersion of polymeric nanoparticles and allowing that the active ingredients to become entrapped within polymeric nanoparticles; and evaporating the dispersion of polymeric nanoparticles having entrapped active ingredients to evaporate the residual monomer and the solvent used as a vehicle for loading the active ingredient.Type: ApplicationFiled: December 7, 2012Publication date: June 13, 2013Applicant: CENTRO DE INVESTIGACION EN QUIMICA APLICADAInventor: Centro De Investigacion En Quimica Aplicada
-
Patent number: 8461202Abstract: Compounds of the general formula (I) or salts thereof, for use as a pharmaceutical composition for treating infectious diseases, especially for treating diseases caused by Helicobacter are disclosed. R1 is an H atom, an X atom or a CXmH3-m radical wherein each X can be the same or different and is a halogen selected from F, Cl, Br or I, and m is an integer between 1 and 3; R2 is an NO2 group, a COOR? group or an SO3R? group; R? is a hydrogen (H) atom or a C1-C6 alkyl group; and n is an integer between 1 and 5.Type: GrantFiled: February 22, 2008Date of Patent: June 11, 2013Assignee: Universidad de ZaragozaInventors: Javier Sancho Sanz, Adrián Velazquez Campoy, Nunilo Cremades Casasin
-
Publication number: 20130142768Abstract: The present invention relates to a method for promoting eye health by administering to a companion animal a composition comprising at least one polyphenol selected from the group consisting of rosemary, rosemary extract, coffeic acid, coffee extract, turmeric extract, cucurmin, blueberry extract, grapeseed extract, rosemarinic acid, tea extract, and mixtures thereof.Type: ApplicationFiled: February 1, 2013Publication date: June 6, 2013Applicant: THE IAMS COMPANYInventor: The IAMS Company
-
Publication number: 20130143831Abstract: The invention provides topical pharmaceutical compositions comprising flurbiprofen, or a pharmaceutically acceptable derivative thereof, in combination with a solubilising system which comprises at least one glycol ether and at least one glycol ester. These are suitable for treating any condition associated with pain, inflammation and/or stiffness, for example sub-dermal pain in the joints or soft tissue.Type: ApplicationFiled: June 28, 2011Publication date: June 6, 2013Applicant: EDKO PAZARLAMA TANITIM TICARET LIMITED SIRKETIInventors: Koral Embil, Ray Figueroa
-
Publication number: 20130136793Abstract: Disclosed is a method for the preparation of easily-swallowed, reliably-dosed, aesthetically-improved tablets of sodium ibuprofen dihydrate, the method comprising the formation of the tablets with punches or presses comprising contact surfaces which are chrome or chrome-plated.Type: ApplicationFiled: December 14, 2012Publication date: May 30, 2013Applicant: ALBEMARLE CORPORATIONInventor: ALBEMARLE CORPORATION
-
Publication number: 20130136792Abstract: A multi phase soft gelatin dosage form comprising at least one preformed solid dosage form and at least one liquid fill phase. The multi phase soft gelatin dosage forms of the present invention are especially useful to combine at least one solid dosage form and at least one liquid phase for single ingestion. Method and apparatus for manufacturing the multiphase soft gelatin dosage forms are also described. The solid phase, liquid phase or coatings may comprise active pharmaceutical ingredients, nutraceuticals, nutritional supplements, therapeutic substances, functional excipients or combinations thereof.Type: ApplicationFiled: June 3, 2011Publication date: May 30, 2013Applicant: ACCUCAPS INDUSTRIES LIMITEDInventors: Peter Draper, James Edward Draper, Beth Marie Okutan
-
Patent number: 8449910Abstract: Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.Type: GrantFiled: September 14, 2012Date of Patent: May 28, 2013Assignee: Horizon Pharma USA, Inc.Inventors: Jerry Xu, George F. Tidmarsh